Scholarlink

Introduction <p>The impacts of prurigo nodularis (PN) on healthcare resource utilization (HCRU) and associated costs are unclear.</p> Methods <p>This retrospective, cross-sectional claims analysis (IQVIA PharMetrics<sup>®</sup> Plus) compared HCRU and costs over 1&#xa0;year in adults with PN versus matched controls (region, payer type, age, sex, year) from 2016 to 2019, and also in patients with PN receiving advanced versus localized/no therapy. For patients with data in multiple calendar years, 1&#xa0;year was randomly selected. Outcomes were compared by chi-square tests, <i>t</i>&#xa0;tests, or negative binomial tests.</p> Results <p>We matched 16,888 patients with PN with 16,888 controls. Most comorbidities (mental health, metabolic conditions, type&#xa0;2 inflammatory diseases) appeared more frequently in patients with PN versus controls. HCRU was significantly (<i>P</i> &lt; 0.001) higher for patients with PN versus controls, including mean (standard deviation, SD) number of outpatient visits (17.0 [15.5] vs 8.1 [10.7]) and proportion of patients with hospitalizations (9.3% vs 5.9%). Mean (SD) total costs were significantly (<i>P</i> &lt; 0.001) greater for patients with PN versus controls ($18,315 [$66,476] vs $8451 [$30,982]).</p> Conclusions <p>Patients with PN receiving advanced therapy had higher HCRU and costs versus localized/no therapy. Patients with PN (particularly those receiving advanced therapies) incurred higher all-cause HCRU burden and associated costs than matched controls.</p> <p><MediaObject ID="MOESM1"> <VideoObject FileRef="MediaObjects/13555_2025_1349_MOESM1_ESM.mp4" VideoID="FFSc-rPK6VaYf-RBf1Mkka"> <Caption Language="En" xml:lang="en"> <CaptionContent> <p>Enhanced feature (slides, video, animation) (MP4 12313 KB)</p> </CaptionContent> </Caption> </VideoObject> </MediaObject></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月8日

查看全文
  • Shawn G. Kwatra,
  • Ashis K. Das,
  • Eunice Chang,
  • Caleb Paydar,
  • Donia Bahloul,
  • Chao Chen,
  • Ryan B. Thomas

摘要

Introduction

The impacts of prurigo nodularis (PN) on healthcare resource utilization (HCRU) and associated costs are unclear.

Methods

This retrospective, cross-sectional claims analysis (IQVIA PharMetrics® Plus) compared HCRU and costs over 1 year in adults with PN versus matched controls (region, payer type, age, sex, year) from 2016 to 2019, and also in patients with PN receiving advanced versus localized/no therapy. For patients with data in multiple calendar years, 1 year was randomly selected. Outcomes were compared by chi-square tests, t tests, or negative binomial tests.

Results

We matched 16,888 patients with PN with 16,888 controls. Most comorbidities (mental health, metabolic conditions, type 2 inflammatory diseases) appeared more frequently in patients with PN versus controls. HCRU was significantly (P < 0.001) higher for patients with PN versus controls, including mean (standard deviation, SD) number of outpatient visits (17.0 [15.5] vs 8.1 [10.7]) and proportion of patients with hospitalizations (9.3% vs 5.9%). Mean (SD) total costs were significantly (P < 0.001) greater for patients with PN versus controls ($18,315 [$66,476] vs $8451 [$30,982]).

Conclusions

Patients with PN receiving advanced therapy had higher HCRU and costs versus localized/no therapy. Patients with PN (particularly those receiving advanced therapies) incurred higher all-cause HCRU burden and associated costs than matched controls.

Enhanced feature (slides, video, animation) (MP4 12313 KB)